Drugs in Phase II clinical trials for the treatment of age-related macular degeneration
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The clinical development of anti-VEGF therapies for the treatment of exudative age-related macular degeneration (wet AMD) has revolutionized ophthalmology. Indeed, it has provided clinicians and patients with treatments that lessen visual loss from in a disease that once was uniformly blinding. Although blindness is yet to be eradicated from AMD, repeated intraocular anti-VEGF injections are required to preserve a patient's vision. Therefore, further advances in this field are necessary. AREAS COVERED: This review provides an overview of the agents that are in mid-stage phase trials for both exudative (wet AMD) and nonexudative macular degeneration (dry AMD). For wet AMD, new agents intend to enhance efficacy, develop alternative delivery such as eye drops, investigate alternate targets and construct sustained release strategies. For advanced dry AMD, the goal is to develop a strategy to slow or stop progressive loss of retinal tissue seen in geographic atrophy, the hallmark of advanced dry AMD. EXPERT OPINION: It is important to develop better more sensitive biomarkers, validating different approvable clinical trial endpoints and stratifying patients on their genetic polymorphisms. These developments should help to progress the already rapidly developing field of macular degeneration therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · cited 1×
“What makes PF-04523655 unique in regard to nucleotide therapy is its short methylated portion possibly facilitating its entry into cells and prevents degradation in vivo [79-82].”
BackgroundRanibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 1×
“Phase III clinical trials with this molecule demonstrate noninferiority of every 8-week administration with aflibercept as compared with every 4-week administration of ranibizumab [53].”
BackgroundComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 1×
“Polymorphisms in two major loci, the 1q32 (CFH, CFHR and F13B), which play a role in the complement system, and 10q26 (ARMS2, HTRA1 and PLEKHA1), which plays roles in oxidation, immunity and extracellular matrix (ECM) maintenance, have been associated with the development and progression of AMD [14-18].”
BackgroundComplement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424 · cited 1×
“Polymorphisms in two major loci, the 1q32 (CFH, CFHR and F13B), which play a role in the complement system, and 10q26 (ARMS2, HTRA1 and PLEKHA1), which plays roles in oxidation, immunity and extracellular matrix (ECM) maintenance, have been associated with the development and progression of AMD [14-18].”
BackgroundHageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 1×
“Polymorphisms in two major loci, the 1q32 (CFH, CFHR and F13B), which play a role in the complement system, and 10q26 (ARMS2, HTRA1 and PLEKHA1), which plays roles in oxidation, immunity and extracellular matrix (ECM) maintenance, have been associated with the development and progression of AMD [14-18].”
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · cited 1×
“As a TKI, it targets several angiogenic kinases including VEGF1/3, PDGR-b and fibroblast growth factor receptor 1 [68].”
BackgroundBrown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265 · cited 1×
“Inflammation in particular the complement system has been implicated in the pathogenesis of AMD [9-13].”
BackgroundDrusen proteome analysis: an approach to the etiology of age-related macular degeneration
Crabb, J. W., Miyagi, M., Gu, X., Shadrach, K., West, K. A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, L., Rayborn, M. E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222551899 · Cited by 1,208 · cited 1×
“CFH can be loosely categorized as an anti-inflammatory [19,20].”
BackgroundA role for local inflammation in the formation of drusen in the aging eye
Anderson, D. H., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01624-0 · Cited by 1,087
A Membrane Receptor for Retinol Binding Protein Mediates Cellular Uptake of Vitamin A
Kawaguchi, R., Yu, J., Honda, J., Hu, J., Whitelegge, J., Ping, P., Wiita, P., Bok, D., & Sun, H. (2007) · Science · doi:10.1126/science.1136244 · Cited by 836
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 1×
“This has been shown to infect photoreceptors and RPE cells with a single intravitreal injection [71].”
BackgroundAnderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727
High-affinity binders selected from designed ankyrin repeat protein libraries
Binz, H. K., Amstutz, P., Kohl, A., Stumpp, M. T., Briand, C., Forrer, P., Grütter, M. G., & Plückthun, A. (2004) · Nature Biotechnology · doi:10.1038/nbt962 · Cited by 656 · cited 1×
“Although they present another alternative to antibody therapy [57], they can also be designed to bind multiple protein targets.”
BackgroundDrusen complement components C3a and C5a promote choroidal neovascularization
Nozaki, M., Raisler, B. J., Sakurai, E., Sarma, J. V., Barnum, S. R., Lambris, J. D., Chen, Y., Zhang, K., Ambati, B. K., Baffi, J. Z., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408835103 · Cited by 650
Binz, H. K., Stumpp, M. T., Forrer, P., Amstutz, P., & Plückthun, A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00896-9 · Cited by 589
Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801 , Involved in Apoptosis
Shoshani, T., Faerman, A., Mett, I., Zelin, E., Tenne, T., Gorodin, S., Moshel, Y., Elbaz, S., Budanov, A., Chajut, A., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2283-2293.2002 · Cited by 546
A prospective study of cigarette smoking and age-related macular degeneration in women
Seddon, J. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140029022 · Cited by 435
Zareparsi, S., Branham, K. E. H., Li, M., Shah, S., Klein, R. J., Ott, J., Hoh, J., Abecasis, G. R., & Swaroop, A. (2005) · The American Journal of Human Genetics · doi:10.1086/431426 · Cited by 371
Anderson, D. H., Talaga, K. C., Rivest, A. J., Barron, E., Hageman, G. S., & Johnson, L. V. (2004) · Experimental Eye Research · doi:10.1016/j.exer.2003.10.011 · Cited by 319
Yehoshua, Z., Alexandre de Amorim Garcia Filho, C., Nunes, R. P., Gregori, G., Penha, F. M., Moshfeghi, A. A., Zhang, K., Sadda, S., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.044 · Cited by 299 · cited 1×
“Off course the study was not powered to answer this particular question and numbers are too small to determine statistical significance [105].”
BackgroundReynolds, R., Hartnett, M. E., Atkinson, J. P., Giclas, P. C., Rosner, B., & Seddon, J. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3928 · Cited by 294
Bora, P. S., Sohn, J.-H., Cruz, J. M. C., Jha, P., Nishihori, H., Wang, Y., Kaliappan, S., Kaplan, H. J., & Bora, N. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.491 · Cited by 249
Corradetti, M. N., Inoki, K., & Guan, K.-L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c400557200 · Cited by 237 · cited 1×
“By targeting the RTP801 gene, the m-TOR pathway is inhibited [77].”
BackgroundMata, N. L., Lichter, J. B., Vogel, R., Han, Y., Bui, T. V., & Singerman, L. J. (2013) · Retina · doi:10.1097/iae.0b013e318265801d · Cited by 157 · cited 1×
“In a recent study, DDA was used as a measure of fenretinide dose, but no statistically significant differences in the magnitude of DDA between the treatment groups were noted [114].”
MethodVives-Bauza, C., Anand, M., Shirazi, A. K., Magrane, J., Gao, J., Vollmer-Snarr, H. R., Manfredi, G., & Finnemann, S. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800706200 · Cited by 155 · cited 1×
“Although A2E is toxic and initiates apoptosis, exposure of A2E to high-energy visible light results in the upregulation of free radicals and increase in inflammatory activation from this fluorophore [26-29], In addition to the oxidative effects of A2E, accumulation of A2E has been shown to alter gene expression that p…”
BackgroundBora, N. S., Kaliappan, S., Jha, P., Xu, Q., Sohn, J.-H., Dhaulakhandi, D. B., Kaplan, H. J., & Bora, P. S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1872 · Cited by 124 · cited 1×
“These factors have all been demonstrated to upregulate the angiogenic factor VEGF [36-38].”
Background
Cited by
Burlina, P. M., Joshi, N., Pekala, M., Pacheco, K. D., Freund, D. E., & Bressler, N. M. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.3782 · Cited by 671
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390
“New pharmacologic agents directed against scar development may provide additional benefit in the therapy of neovascular AMD (Tolentino et al., 2015).”
BackgroundMacrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Kaneda, M. M., Cappello, P., Nguyen, A. V., Ralainirina, N., Hardamon, C. R., Foubert, P., Schmid, M. C., Sun, P., Mose, E., Bouvet, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1346 · Cited by 326
VEGF regulates local inhibitory complement proteins in the eye and kidney
Keir, L. S., Firth, R., Aponik, L., Feitelberg, D., Sakimoto, S., Aguilar, E., Welsh, G. I., Richards, A., Usui, Y., Satchell, S. C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86418 · Cited by 154
“Complement inhibition in ARMD, including GA, is an area of active study, with several agents currently in phase 2/3 trials (54).”
BackgroundHallam, D., Collin, J., Bojic, S., Chichagova, V., Buskin, A., Xu, Y., Lafage, L., Otten, E. G., Anyfantis, G., Mellough, C., et al. (2017) · Stem Cells · doi:10.1002/stem.2708 · Cited by 75
Metadata
- Authors
- Tolentino, M. J., Dennrick, A., John, E., & Tolentino, M. S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2014-09-22
- Volume
- 24
- Issue
- 2
- Pages
- 183-199
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2113083452
- Cited by
- 58
- References
- 31
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.